Gene therapy continues to make progress: Clinical and regulatory perspectives

Current Gene Therapy

Volumn 9, Issue 5, 2009, Pages 327-328

  Castro, Maria G ^a   Lowenstein, Pedro R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 ANTIGEN; INTERLEUKIN 2 RECEPTOR GAMMA; PARVOVIRUS VECTOR; RETROVIRUS VECTOR;

ADENOSINE DEAMINASE DEFICIENCY; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CAUSE OF DEATH; CHRONIC GRANULOMATOUS DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; GENE INSERTION; GENE THERAPY; HUMAN; LEUKEMIA; LEUKEMIA REMISSION; ONCOGENE; PATIENT SAFETY; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; THERAPY EFFECT; TREATMENT FAILURE; VIRAL GENE DELIVERY SYSTEM; X LINKED SEVERE COMBINED IMMUNODEFICIENCY;

CLINICAL TRIALS AS TOPIC; GENE THERAPY; HUMANS;

EID: 73449146296     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652309789753374     Document Type: Editorial

References (14)

1. Available from: http://www.wiley.co.uk/genmed/clinical/. J Gene Med 2009; Wiley Publishers; [updated 8/19/09]
2. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009; 360: 447-58.
3. Hershfield MS. Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy. Semin Hematol 1998; 35: 291-8.
4. One of three successfully treated CGD patients in a Swiss-German gene therapy trial died due to his underlying disease: a position statement from the European Society of Gene Therapy (ESGT). J Gene Med 2006; 8: 1435.
5. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669-72.
6. Chinen J, Davis J, De Ravin SS, et al. Gene therapy improves immune function in preadolescents with X-linked severe combined immunodeficiency. Blood 2007; 110: 67-73.
7. Fischer A, Cavazzana-Calvo M. Gene therapy of inherited diseases. Lancet 2008; 371: 2044-7.
8. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255-6.
9. Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 2008; 118: 3143-50.
10. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-9.
11. Evans CH, Ghivizzani SC, Robbins PD. Arthritis gene therapy's first death. Arthritis Res Ther 2008; 10: 110.
12. Frank KM, Hogarth DK, Miller JL, et al. Investigation of the cause of death in a gene-therapy trial. N Engl J Med 2009; 361: 161-9.
13. Bates DW. Drugs and adverse drug reactions: how worried should we be? JAMA 1998; 279: 1216-7.
14. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200-5.